KEYNOTE-641 trial for metastatic castration-resistant prostate cancer was discontinued due to lack of survival benefits with Keytruda combination. KEYNOTE-789 trial in metastatic nonsquamous non-small ...

Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday that the companies would halt two late-stage combination trials for cancer therapy Keytruda in melanoma and colorectal cancer ...

Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda ® (pembrolizumab) in combination with other therapies to treat multiple myeloma, ...

Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima, in patients with certain types ...

Merck & Co.’s Keytruda has risen from the ashes with a positive stomach cancer trial readout. But there’s some reconciliation to do with a past failure that led to the withdrawal of an accelerated ...

Keytruda’s KEYNOTE-189 trial marked a watershed moment in the history of lung cancer drug development by showing a monster survival benefit. Now, Merck & Co. is giving a five-year look at the data ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) Friday announced positive results of Phase 3 trials with its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in various cancers. In the Phase 3 KEYNOTE-756 ...

Summit Therapeutics' ivonescimab shows promise potential in two phase 3 trials for lung cancer. Stifel analyst sees an opportunity for two updates from Summit Therapeutics' Chinese partner Akeso in ...

CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...